Obsessive-Compulsive Symptoms in Schizophrenia: an Up-To-Date Review of Literature.


Journal

Current psychiatry reports
ISSN: 1535-1645
Titre abrégé: Curr Psychiatry Rep
Pays: United States
ID NLM: 100888960

Informations de publication

Date de publication:
01 07 2019
Historique:
entrez: 3 7 2019
pubmed: 3 7 2019
medline: 4 4 2020
Statut: epublish

Résumé

This review will aim to summarize the current body of epidemiological, clinical and therapeutic knowledge concerning specific co-occurrence of obsessive-compulsive symptoms (OCSs) and schizophrenia spectrum disorder. Almost 30% of the patients with schizophrenia display OCS, and three main contexts of emergence are identified: prodromal symptoms of schizophrenia, co-occurrence of OCS and schizophrenia and antipsychotics-induced OCS. Recent clinical studies show that patients with SZ and OCS have more severe psychotic and depressive symptoms, higher suicidality and lower social functioning. A recent cognitive investigation found that OCS and delusions share specific metacognitive profiles, particularly through a heightened need to control thoughts. Finally, a recent cross-sectional study of clozapine-induced OCS found a dose-response relationship between clozapine and OCS. OCS appeared reliably as linked to poorer outcomes among patients with schizophrenia. However, the specific clinical value of OCS among other prodromal symptoms of schizophrenia remains unknown.

Identifiants

pubmed: 31263973
doi: 10.1007/s11920-019-1051-y
pii: 10.1007/s11920-019-1051-y
doi:

Substances chimiques

Antipsychotic Agents 0
Clozapine J60AR2IKIC

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

64

Références

J Clin Psychiatry. 1999 Jun;60(6):364-5
pubmed: 10401913
Pharmacopsychiatry. 2000 Nov;33(6):236-8
pubmed: 11147933
Psychiatr Pol. 2002 Nov-Dec;36(6 Suppl):283-6
pubmed: 12647450
J Clin Psychiatry. 1992 Dec;53(12):439-42
pubmed: 1487472
Int J Neuropsychopharmacol. 2005 Mar;8(1):107-29
pubmed: 15450126
Schizophr Res. 2004 Dec 15;72(1):5-9
pubmed: 15531402
J Clin Psychiatry. 2004;65 Suppl 14:11-7
pubmed: 15554783
CNS Drugs. 2004;18(14):989-1010
pubmed: 15584769
Schizophr Res. 1992 Mar;6(3):201-8
pubmed: 1571313
J Psychiatry Neurosci. 2005 May;30(3):187-93
pubmed: 15944743
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
Prog Neuropsychopharmacol Biol Psychiatry. 2006 May;30(3):327-37
pubmed: 16412548
Ther Drug Monit. 2006 Jun;28(3):303-7
pubmed: 16778711
J Nerv Ment Dis. 2007 Sep;195(9):765-8
pubmed: 17984777
J Clin Psychopharmacol. 2008 Apr;28(2):214-8
pubmed: 18344733
Psychiatry Res. 2008 May 30;159(1-2):133-9
pubmed: 18406469
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1386-92
pubmed: 18407391
Schizophr Res. 2009 Mar;108(1-3):170-5
pubmed: 19097751
J Clin Psychiatry. 2009 Jan;70(1):70-82
pubmed: 19192458
J Clin Psychiatry. 2009 Jun;70(6):863-8
pubmed: 19422759
Clin Neuropharmacol. 2009 Jul-Aug;32(4):227-9
pubmed: 19644230
Eur J Med Res. 2009 Aug 12;14(8):367-8
pubmed: 19666398
Psychiatry Res. 2009 Nov 30;170(1):52-60
pubmed: 19800695
Schizophr Bull. 2011 Jul;37(4):811-21
pubmed: 19959704
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):323-30
pubmed: 20015461
Cogn Neuropsychiatry. 2010 Nov;15(6):531-48
pubmed: 20446128
Acta Psychiatr Scand. 2011 Feb;123(2):136-46
pubmed: 20880068
Schizophr Res. 2011 Jan;125(1):62-8
pubmed: 21074975
J Psychiatr Res. 2011 Sep;45(9):1140-5
pubmed: 21440906
Psychol Med. 2011 Nov;41(11):2361-73
pubmed: 21466748
J Clin Psychopharmacol. 2011 Jun;31(3):375-6
pubmed: 21532362
Schizophr Bull. 2013 Jan;39(1):151-60
pubmed: 21799212
Compr Psychiatry. 2012 Jul;53(5):480-3
pubmed: 22036006
Aust N Z J Psychiatry. 2012 Feb;46(2):161-9
pubmed: 22311532
J Affect Disord. 2012 May;138(3):352-9
pubmed: 22331022
Riv Psichiatr. 2012 Mar-Apr;47(2):106-15
pubmed: 22622247
Schizophr Bull. 2013 Nov;39(6):1261-71
pubmed: 23104864
Int Clin Psychopharmacol. 2013 Mar;28(2):96-8
pubmed: 23211492
Ann Clin Psychiatry. 2013 Feb;25(1):11-6
pubmed: 23376865
BMC Psychiatry. 2013 May 30;13:156
pubmed: 23721089
Front Pharmacol. 2013 Aug 09;4:99
pubmed: 23950745
World J Psychiatry. 2013 Sep 22;3(3):50-6
pubmed: 24255875
Ann Gen Psychiatry. 2013 Dec 12;12(1):40
pubmed: 24330737
Schizophr Res. 2014 Feb;152(2-3):458-68
pubmed: 24361303
Compr Psychiatry. 2014 May;55(4):1015-21
pubmed: 24411931
Compr Psychiatry. 2014 May;55(4):896-903
pubmed: 24445116
Schizophr Bull. 2014 Sep;40(5):946-8
pubmed: 25096790
JAMA Psychiatry. 2014 Nov;71(11):1215-21
pubmed: 25188738
Curr Psychiatry Rep. 2014 Nov;16(11):510
pubmed: 25256097
Schizophr Bull. 2015 Sep;41(5):1076-83
pubmed: 25512596
Harv Rev Psychiatry. 2015 Jan-Feb;23(1):19-27
pubmed: 25563566
Psychiatry Res. 2015 Nov 30;230(1):50-5
pubmed: 26260567
CNS Drugs. 2015;29(10):819-32
pubmed: 26482261
Adv Med. 2014;2014:317980
pubmed: 26556409
JAMA Psychiatry. 2016 Feb;73(2):113-20
pubmed: 26719911
Psychopharmacology (Berl). 1989;99 Suppl:S18-27
pubmed: 2682729
J Psychiatr Pract. 2016 Mar;22(2):111-6
pubmed: 27138079
Schizophr Bull. 2016 Sep;42(5):1290-302
pubmed: 27143795
Psychiatry Res. 2016 Dec 30;246:119-128
pubmed: 27690134
World J Psychiatry. 2016 Dec 22;6(4):449-455
pubmed: 28078209
J Affect Disord. 2017 Aug 15;218:217-226
pubmed: 28477500
BMC Psychiatry. 2017 Jun 29;17(1):233
pubmed: 28662637
Clin Neuropharmacol. 2017 Nov/Dec;40(6):243-245
pubmed: 28976410
Curr Psychiatry Rep. 2017 Nov 7;19(12):103
pubmed: 29110139
Psychol Med. 2018 Dec;48(16):2668-2675
pubmed: 29455687
Eur Arch Psychiatry Clin Neurosci. 2019 Mar;269(2):245-255
pubmed: 29520640
Schizophr Res. 2018 Nov;201:196-203
pubmed: 29941294
Ir J Psychol Med. 2018 Jun;35(2):89-94
pubmed: 30115193
Br J Psychiatry. 1986 Nov;149:661-2
pubmed: 3545358
Am J Psychiatry. 1986 Apr;143(4):437-41
pubmed: 3953886
J Clin Psychiatry. 1994 Mar;55 Suppl:24-31
pubmed: 7521326
J Clin Psychiatry. 1995 Sep;56(9):423-9
pubmed: 7545159
Am J Psychiatry. 1999 Feb;156(2):286-93
pubmed: 9989565

Auteurs

Chloé Tezenas du Montcel (C)

AP-HP, DHU PePSY, Hôpitaux Universitaires Henri-Mondor, Pôle de Psychiatrie, 94000, Créteil, France.
Fondation FondaMental, 94000, Créteil, France.
UPEC, Faculté de médecine, Université Paris-Est, 94000, Créteil, France.

Antoine Pelissolo (A)

AP-HP, DHU PePSY, Hôpitaux Universitaires Henri-Mondor, Pôle de Psychiatrie, 94000, Créteil, France.
Fondation FondaMental, 94000, Créteil, France.
UPEC, Faculté de médecine, Université Paris-Est, 94000, Créteil, France.
INSERM, U955, team 15, 94000, Créteil, France.

Franck Schürhoff (F)

AP-HP, DHU PePSY, Hôpitaux Universitaires Henri-Mondor, Pôle de Psychiatrie, 94000, Créteil, France.
Fondation FondaMental, 94000, Créteil, France.
UPEC, Faculté de médecine, Université Paris-Est, 94000, Créteil, France.
INSERM, U955, team 15, 94000, Créteil, France.

Baptiste Pignon (B)

AP-HP, DHU PePSY, Hôpitaux Universitaires Henri-Mondor, Pôle de Psychiatrie, 94000, Créteil, France. baptistepignon@yahoo.fr.
Fondation FondaMental, 94000, Créteil, France. baptistepignon@yahoo.fr.
UPEC, Faculté de médecine, Université Paris-Est, 94000, Créteil, France. baptistepignon@yahoo.fr.
INSERM, U955, team 15, 94000, Créteil, France. baptistepignon@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH